Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.38 |
| ▸ | GCGR | P47871 | 2/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1544604 | 0.84 | NPC1 (0.51) | ALDH1A1HSD11B1MEN1KMT2ANPC1 | |
| SCHEMBL1544137 | 0.81 | HSD11B1 (0.56) | ALDH1A1HSD11B1KMT2AKDM4ETSHR | |
| SCHEMBL12803376 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HSD11B1MEN1KMT2AKDM4E | |
| SCHEMBL6402595 | 0.81 | ALDH1A1 (0.59) | ALDH1A1HSD11B1MEN1KMT2ANPC1 | |
| SCHEMBL8270966 | 0.81 | ADORA2A (0.33) | ALDH1A1HSD11B1MEN1KMT2ANPC1 | |
| SCHEMBL4184528 | 0.81 | HSD11B1 (0.43) | ALDH1A1HSD11B1MEN1KMT2ANPC1 | |
| SCHEMBL4877749 | 0.80 | HSD11B1 (0.39) | ALDH1A1HSD11B1GAAHSD17B10 | |
| SCHEMBL2847331 | 0.80 | ALDH1A1 (0.36) | ALDH1A1HSD11B1MEN1KMT2ANPC1 | |
| SCHEMBL392717 | 0.80 | HSD11B1 (0.53) | ALDH1A1HSD11B1KMT2ANPC1TSHR | |
| SCHEMBL14076996 | 0.80 | ALDH1A1 (0.47) | ALDH1A1HSD11B1MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212644-B1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF DIABETES | APOGLYX AB (SE) | 2021-05-05 | — | — | EP | disclosed |
| CN-107001351-B | Derivatives of 2- (1,2, 4-triazol-3-ylsulfanyl) -N-1,3, 4-thiadiazol-2-ylacetamide useful in the treatment of, in particular, diabetes | 阿波格吕克斯有限公司 | 2020-06-05 | — | — | CN | disclosed |
| US-10011597-B2 | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | APOGLYX AB (SE) | 2018-07-03 | — | — | US | disclosed |
| US-20170320869-A1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES | APOGLYX AB (SE) | 2017-11-09 | — | — | US | disclosed |
| EP-3212644-A1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES | Apoglyx AB (SE) | 2017-09-06 | — | — | EP | disclosed |
| CN-107001351-A | Derivative available for the treatment particularly yl acetamide of 2 (the base sulfanyl of 1,2,4 triazole 3) 1,3,4 thiadiazoles of N 2 of diabetes | 阿波格吕克斯有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2016066696-A1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES | APOGLYX AB (SE) | 2016-05-06 | — | — | WO | disclosed |
| EP-1817037-B1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-20120295204-A1 | PROCESSING METHOD OF LITHOGRAPHIC PRINTING PLATE PREURSOR | FUJIFILM CORPORATION (JP) | 2012-11-22 | — | — | US | disclosed |
| US-20120295204-A1 | PROCESSING METHOD OF LITHOGRAPHIC PRINTING PLATE PREURSOR | FUJIFILM CORPORATION (JP) | 2012-11-22 | — | — | US | disclosed |
| CN-1984907-A | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-06-20 | — | — | CN | disclosed |
| US-20070128550-A1 | Method for preparation of lithographic printing plate and lithographic printing plate precursor | FUJIFILM CORPORATION (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070128550-A1 | Method for preparation of lithographic printing plate and lithographic printing plate precursor | FUJIFILM CORPORATION (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070020563-A1 | Method for preparation of lithographic printing plate and lithographic printing plate precursor | FUJI PHOTO FILM CO., LTD. | 2007-01-25 | — | — | US | disclosed |
| US-20070020563-A1 | Method for preparation of lithographic printing plate and lithographic printing plate precursor | FUJI PHOTO FILM CO., LTD. | 2007-01-25 | — | — | US | disclosed |
| CN-1894241-A | \"1, 2, 4\" oxadiazoles as modulators of metabotropic glutamate receptor-5 | ASTRAZENECA AB (SE) | 2007-01-10 | — | — | CN | disclosed |
| WO-2006058753-A1 | TRIAZOLE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULAIONT OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | ALDH1A1 185/4885HSD11B1 291/4885MEN1 155/4885 |
| US-20060122397-A1 | Exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR5 receptor; neurological disorders, psychiatric disorders, acute and chronic pain | GRM5, GRIK5, GRM1 | ALDH1A1 2602/4885HSD11B1 3192/4885MEN1 4597/4885 |
| US-20050272779-A1 | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM5, GRIK5, GRM2 | ALDH1A1 3875/4885HSD11B1 2450/4885MEN1 3387/4885 |
| US-20170320869-A1 | DERIVATIVES OF 2-(1,2,4-TRIAZOL-3-YLSULFANYL)-N-1,3,4-THIADIAZOL-2-YL ACETAMIDE WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA DIABETES | AQP1, AQP3, AQP4 | ALDH1A1 1327/4885HSD11B1 3035/4885MEN1 2576/4885 |
| US-10011597-B2 | Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes | AQP1, AQP3, AQP4 | ALDH1A1 1327/4885HSD11B1 3035/4885MEN1 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.